| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-10-31 | Actelion (Switzerland) ZoBio (The Netherlands) | conformationally selective fragment ligands for an oncology target | services |
Technology - Services - Cancer - Oncology | Services contract | |
| 2013-10-31 | Merck KGaA, Merck Serono (Germany) The Lead Discovery Center (LDC) (Germany) | lead candidates to multiple drug targets | R&D |
Cancer - Oncology - Immunological diseases - Autoimmune diseases - Endocrine diseases | R&D agreement | |
| 2013-10-31 | HighPoint Solutions (USA) InnoPeritus (Switzerland) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2013-10-31 | Stallergenes (France) Greer Laboratories (USA) | Oralair® | grass allergy | commercialisation |
Allergic diseases - Immunological diseases | Commercialisation agreement |
| 2013-10-30 | Royal DSM (The Netherlands) Opthea (Australia) | OPT-302 (soluble form of human VEGFR-3) | wet (neovascular) age-related macular degeneration (wet AMD) | development |
Ophtalmological diseases | Production agreement |
| 2013-10-30 | Photocure (Norway) Galderma (Switzerland) | Visonac® | moderate to severe acne | Dermatological diseases | Development agreement | |
| 2013-10-29 | AOP Orphan Pharmaceuticals (Austria) Ferrer Internacional (Spain) | Adasuve® (Staccato® Loxapine) | commercialisation |
Mental diseases - CNS diseases | Commercialisation agreement | |
| 2013-10-29 | Sanofi Pasteur (France) Bill & Melinda Gates Foundation | collaboration |
Infectious diseases | Collaboration agreement | ||
| 2013-10-29 | GSK (UK) Bill & Melinda Gates Foundation | thermostable adjuvants including adjuvant AS01 | collaboration |
Infectious diseases | Collaboration agreement | |
| 2013-10-28 | Paion (Germany) Hana Pharmaceutical (South Korea) | remimazolam | sedation, general anaesthesia | licensing |
CNS diseases | Licensing agreement |
| 2013-10-28 | Stada (Germany) Apotex (Canada) | Grastofil® filgrastim - biosimilar version of recombinant human granulocyte colony stimulating factor (G-CSF) | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-10-28 | Open Monoclonal Technology (USA) Merck KGaA, Merck Serono (Germany) | use of OmniRat platform to generate antibodies against several targets selected by Merck KGaA | Technology - Services | Services contract | ||
| 2013-10-25 | CleveXel Pharma (France) Dynamix Pharmaceuticals (Israel) | DNX-04042 | rheumatoid arthritis | R&D |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | R&D agreement |
| 2013-10-24 | Royal DSM (The Netherlands) Sanquin Blood Supply Foundation (The Netherlands) | monoclonal antibody used for the recovery and purification of coagulation factor IX from human blood | manufacturing |
Hematological diseases - Genetic diseases - Rare diseases | Production agreement | |
| 2013-10-24 | Merck Serono (Germany) Selvita (Poland) | small molecule based drugs targeting proteins involved in cancer cell metabolism | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-10-24 | Atheris Laboratories (Switzerland) Debiopharm (Switzerland) | Atheris “Reverse-Discovery”™ lead optimization platform | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2013-10-23 | BioLineRx (Israel) Yissum Research Development Company of the Hebrew University of Jerusalem (Israel) B.G. Negev Technologies (Israel) Applications (Israel) Hadasit Medical Research Services and Development (Israel) | BL-9020 | type 1 diabetes | licensing |
Metabolic diseases | Licensing agreement |
| 2013-10-23 | PharmaCell (The Netherlands) Dendreon (USA) | Provenge® (sipuleucel-T) | prostate cancer | manufacturing |
Cancer - Oncology | Production agreement |
| 2013-10-23 | Umecrine Cognition (Sweden) Clevexel Pharma (France) | hepatic encephalopathy | development |
Hepatic diseases - CNS diseases | Development agreement | |
| 2013-10-22 | Orion Corporation (Finland) Phyxius Pharma | Simdax® (levosimendan) | prevention of Low Cardiac Output Syndrome (LCOS) in cardiac surgery patients | development |
Cardiovascular diseases | Development agreement |
